These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15232173)

  • 1. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection.
    Batzloff M; Yan H; Davies M; Hartas J; Good M
    Indian J Med Res; 2004 May; 119 Suppl():104-7. PubMed ID: 15232173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
    Bessen D; Fischetti VA
    J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping a conserved conformational epitope from the M protein of group A streptococci.
    Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
    Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct.
    Olive C; Batzloff M; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Indian J Med Res; 2004 May; 119 Suppl():88-94. PubMed ID: 15232170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
    Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein.
    Lin HX; Huang DY; Wang Y; Lu CP; Fan HJ
    Vaccine; 2011 Sep; 29(40):7027-34. PubMed ID: 21807055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
    Bronze MS; Courtney HS; Dale JB
    J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
    Good MF; Pandey M; Batzloff MR; Tyrrell GJ
    Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
    Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
    Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
    J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.